Discovery & development
Pipeline
Three programs move together through the seed round, then into the clinic on Series A, then into pivotal trials on Series B. The diagnostic tracks alongside the drugs so the two can be approved as a pair.
Discovery and development
EGFR–V-001 ADC
TNBC with EGFR-high & PIK3CA mutations
Intended to support FDA Fast Track designation request to accelerate Phase 1/2A trials
V-001 Parenteral
IV formulation for metastatic cancer with MDR
Intended to support FDA Fast Track designation request to accelerate Phase 1/2A trials
HER-2–V-001 ADC
Breast cancer with PIK3CA mutations & MDR
Intended to support FDA Fast Track designation request to accelerate Phase 1/2A trials